<p>An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Thursday.</p>.<p>Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) had recently written a letter to Drugs Controller General of India (DCGI) for approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating Covid-19 pandemic situation in some countries, the sources said.</p>.<p>"The subject expert committee (SEC) of the CDSCO on Wednesday deliberated on the issue and recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/india-sees-197-fresh-covid-19-cases-active-cases-decline-to-2309-1180307.html" target="_blank">India sees 197 fresh Covid-19 cases, active cases decline to 2,309</a></strong></p>.<p>The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022 and also in children aged 7-11 years on June 28, 2022 subject to certain conditions.</p>.<p>Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.</p>.<p>In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with SII for development and commercialization of NVX-CoV2373, its Covd-19 vaccine candidate in India and low-and-middle-income countries.</p>
<p>An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Thursday.</p>.<p>Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) had recently written a letter to Drugs Controller General of India (DCGI) for approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating Covid-19 pandemic situation in some countries, the sources said.</p>.<p>"The subject expert committee (SEC) of the CDSCO on Wednesday deliberated on the issue and recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/india-sees-197-fresh-covid-19-cases-active-cases-decline-to-2309-1180307.html" target="_blank">India sees 197 fresh Covid-19 cases, active cases decline to 2,309</a></strong></p>.<p>The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022 and also in children aged 7-11 years on June 28, 2022 subject to certain conditions.</p>.<p>Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.</p>.<p>In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with SII for development and commercialization of NVX-CoV2373, its Covd-19 vaccine candidate in India and low-and-middle-income countries.</p>